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• CYP2D6 is genetically polymorphic leading
to dramatic variability in metabolic activity.
diplotypes into phenotypes or assign
activity scores based on half number
increments. These assumptions were tested
to assess whether reclassification and
recalibration is necessary.
diplotypes that are distinct from each other
and the other phenotypes. The empirically
estimated relative activities of the four allele
types and individual EM and IM alleles are
different from those previously assumed.
CYP2D6 phenotype classification systems
individualized dosing of CYP2D6 dependent
drugs.
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AIMS
A prospectively enrolled patient cohort was used to assess whether the
prediction of CYP2D6 phenotype activity from genotype data could be
improved by reclassification of diplotypes or alleles.Phenotype classification systems collapse
METHODS
Three hundred and fifty-five patients receiving tamoxifen 20mg were
genotyped for CYP2D6 and tamoxifen metabolite concentrations were
measured. The endoxifen : N-desmethly-tamoxifen metabolic ratio, as
a surrogate of CYP2D6 activity, was compared across four diplotypes
(EM/IM, EM/PM, IM/IM, IM/PM) that are typically collapsed into an in-
termediate metabolizer (IM) phenotype. The relative metabolic activity
of each allele type (UM, EM, IM, and PM) and each EM and IM allele was
estimated for comparison with the activity scores typically assigned, 2,
1, 0.5 and 0, respectively.WHAT THIS STUDY ADDS
• The IM phenotype is comprised of RESULTS
Each of the four IM diplotypes have distinct CYP2D6 activity from each
other and from the EM and PM phenotype groups (each P< 0.05).
Setting the activity of an EM allele at 1.0, the relative activities of a UM, IM
and PM allele were 0.85, 0.67 and 0.52, respectively. The activity of the EM
alleles were statistically different (P< 0.0001), with the CYP2D6*2 allele
(scaled activity = 0.63) closer in activity to an IM than an EM allele. The
activity of the IM alleles were also statistically different (P=0.014).require additional calibration to improve
CONCLUSION
The current systems for translating CYP2D6 genotype into phenotype
are not optimally calibrated, particularly in regards to IM diplotypes
and the *2 allele. Additional research is needed to improve the
prediction of CYP2D6 activity from genetic data for individualized
dosing of CYP2D6 dependent drugs.015 The British Pharmacological Society
CYP2D6 diplotype and allele activityIntroduction MethodsCYP2D6 is one of the primary enzymes responsible for
the metabolic activation or inactivation of exogenous
compounds. It is estimated that approximately 25% of
drugs are metabolized by CYP2D6 [1], including many
analgesics, antidepressants and cytotoxics. There is sub-
stantial inter-patient variability in CYP2D6 activity, which
is partly caused by genetic variation [2]. The CYP2D6
gene is highly polymorphic, with over a hundred allelic
variants [3] and gene multiplications, deletions and other
structural variants [4].
CYP2D6 activity, or phenotype, can be used to indi-
vidualize dosing of certain drugs [5, 6]. The extensive
genetic heterogeneity in CYP2D6 makes phenotype
prediction very complicated. The most common CYP2D6
alleles have been grouped by functional activity classifi-
cations with descending activity: ultra-rapid (UM), exten-
sive (EM), intermediate (IM) or poor (PM) metabolism. A
given patient has two alleles, giving them 10 possible
allelic combinations, or diplotypes (UM/UM, UM/EM, EM/
EM, etc.). These diplotypes are collapsed into four pheno-
types, UM, EM, IM or PM, using either a translation table
or a quantitative activity scoring system [7, 8].
Tamoxifen is a selective oestrogen receptor modulator
used primarily in the treatment of oestrogen receptor
positive breast cancer, and is the first line for use in
pre-menopausal patients [9, 10]. Tamoxifen and its major
metabolite N-desmethyl-tamoxifen are weakly anti-
oestrogenic, but are metabolically activated via CYP2D6
to the more potent anti-oestrogen endoxifen [11, 12]. Pa-
tients with lower CYP2D6 metabolic activity have lower
conversion of N-desmethyl-tamoxifen to endoxifen, which
may be associated with decreased treatment effectiveness
[13, 14]. An immense research effort has been dedicated
to determining whether patients with low activity CYP2D6
genotypes receive less benefit from tamoxifen treatment
[15–18]. However, the results of these studies are highly
controversial [19–21] and at this time CYP2D6 genotyping
is not recommended prior to tamoxifen initiation.
In a previous manuscript, we confirmed that steady-
state endoxifen exposure is dependent on CYP2D6 phe-
notype and demonstrated that increasing the tamoxifen
dose to 40mg in IM (but not PM) patients normalizes the
endoxifen concentrations with that of EM (or UM) pa-
tients remaining on 20mg [22]. Although the clinical use-
fulness of genotype-guided tamoxifen dosing remains
unproven, this large dataset of steady-state metabolite
data and comprehensive CYP2D6 genotyping could be
useful for assessing CYP2D6 phenotype prediction sys-
tems. The purpose of this analysis was to determine
whether any of the diplotypes currently classified as IM
phenotype should be reclassified, and to estimate the
relative activity of each allele type (UM, EM, IM, PM) and
each EM and IM allele to assess the calibration of the
activity scoring systems currently in use.Clinical cohort
Data included in this analysis were collected during the
expansion phase of a prospective CYP2D6-genotype-
guided tamoxifen dose escalation study, Lineberger
Comprehensive Cancer Center (LCCC) 0801. The objec-
tive of the clinical study was to determine whether in-
creasing the daily tamoxifen dose to 40mg in patients
with CYP2D6 genotypes that predict reduced activity
CYP2D6 phenotype (IM or PM as defined below) would
normalize their endoxifen concentrations with that of
patients with high predicted CYP2D6 activity phenotypes
(EM or UM) treated with the standard 20mg dose. Pa-
tients were treated with the genotype-determined dose
for the 4month duration of the study. Details of the inclu-
sion criteria, study methodology and primary findings for
the original 122 patient cohort have been previously
published [22]. Briefly, women 18 years or older who
had been taking tamoxifen 20mg for at least 4months
were eligible for enrolment. Relevant exclusion criteria
included ECOG performance status >2, impaired kidney
or liver function or concurrent use of a moderate or
strong CYP2D6 inhibitor. This is the initial analysis of an
expansion cohort that brought the total study enrolment
to 500 patients. Due to a modification to the endoxifen
assay occurring between analysis of the original and
expansion cohort samples, only patients from the expan-
sion cohort were eligible for this analysis (Supplementary
Figure S1). This study was approved by the institutional
review boards of the University of North Carolina at
Chapel Hill and all other participating institutions. All pa-
tients signed informed consent prior to participation.
Genotyping and CYP2D6 phenotype activity
prediction
Genomic DNA was purified from whole blood collected
at study enrolment and genotyped in a CLIA-certified
laboratory using the AmpliChip® CYP450 test (Roche Di-
agnostics, Indianapolis, IN, USA). This chip can identify
20 distinct CYP2D6 alleles and seven known duplications
(denoted by XN). Each of these alleles can be categorized
by activity: UM, EM, IM or PM (Table 1A), and the combina-
tion of any two alleles represents the patient’s diplotype.
These diplotypes are then collapsed into four phenotype
categories (UM, EM, IM, or PM) (Table 1B). This particular
system for converting diplotype to phenotype is identical
to that used in the prospective clinical study to deter-
mine which patients remained at 20mg (UM and EM)
and which received a dose increase (IM and PM). The
phenotype classification system was based on the most
convincing evidence of association between genotype
and tamoxifen treatment outcomes from Schroth et al.
[18]. Because there were few UM patients (n=5) this
phenotype was excluded from phenotype comparisons.
An additional four patients who carried UM alleles, butBr J Clin Pharmacol / 80:5 / 1123
Table 1A
Transformation of CYP2D6 genotype to allelic activity
Activity Genotypes Allele
High *1XN, *2XN, *35XN UM
Normal *1, *2, and *35 EM
Reduced *9, *10, *17, *29, *36, *41, *17XN, *41XN IM
None *3, *4, *5, *6, *7, *8, *11,*15, *19, *20, *40, *4XN PM
Table 1B
Transformation of diplotype to activity phenotype
Phenotype Diplotypes
UM* UM/UM†, UM/EM†
EM EM/EM, UM/IM†, UM/PM†
IM EM/IM, EM/PM, IM/IM, IM/PM
PM PM/PM
*Excluded from phenotype comparisons †Excluded from diplotype comparisons
D. L. Hertz et al.were not UM phenotype, were excluded from diplotype
analyses which include only three phenotypes com-
prised of six diplotypes (EM: EM/EM, IM: EM/IM, EM/PM,
IM/IM, IM/PM and PM: PM/PM).
Tamoxifen and metabolite concentrations
Blood samples were collected from each patient at
study enrolment, when all patients had been on 20mg
tamoxifen for at least 4months. Steady-state plasma con-
centrations of tamoxifen (Z isomer only), (Z)-4-hydroxy-ta-
moxifen (4-OH-tam), N-desmethyl-tamoxifen (N-DM-tam,
Z isomer only) and (Z)-4-hydroxy-N-desmethyl-tamoxifenTable 2
Demographic data for all eligible patients (n = 355) and broken down by CYP2
All patients (n = 355)
Age (years) Median 52
Range 24–95
Weight (kg) Median 71.0
Range 32.1–149.1
Race White 83.0%
Black 14.7%
Other 2.3%
Months on tamoxifen prior to study Median 10.1
Range 3.4–116.3
CYP2D6 weak inhibitor use Citalopram 4.0%
Escitalopram 4.0%
Venlafaxine 9.1%
Other 0.9%
*Comparison across EM, IM and PM phenotype patients (UM not included)
1124 / 80:5 / Br J Clin Pharmacol(endoxifen; 10% (E), 90% (Z)) were measured using a
h.p.l.c.-MS/MS (API 3200) assay method developed using
diphenhydramine as the internal standard and liquid–
liquid extraction as previously described with minor modi-
fication [22]. Tamoxifen, 4-OH-tam, N-DM-tam, endoxifen
and diphenhydramine were stable for 28h and the lower
limit of quantification was 0.3ng ml–1 for each analyte
using 200μl of plasma. Variability was minimized in the
method by using glass tubes and formic acid as part of
the mobile phase. E isomers of each analyte eluted prior
to the Z isomer. This analysis focuses primarily on the
baseline (at study enrolment, all patients on 20mg) meta-
bolic ratio of endoxifen to N-DM-tam (end : N-DM-tam).
However, endoxifen concentrations at baseline and at
4months (UM and EM patients on 20mg, IM and PM on
40mg) are used in some secondary analyses.
Statistical methods
Endoxifen and end : N-DM-tam ratio descriptive data are
reported using medians and standard deviations. Base-
line demographic comparisons across phenotype groups
(excluding UM) were carried out via Fisher’s exact (cate-
gorical data) and Kruskal–Wallis (continuous data) tests.
Comparisons of metabolite concentrations across phe-
notypes and diplotypes (excluding UM alleles) and esti-
mation of the percentage of variance explained was
carried out via analysis of variance (ANOVA) and Kruskal–
Wallis tests. The activity score modeling was performed
using linear regression with each allele (UM, EM, IM, or
PM) its own parameter. After initial modelling the activity
of an EM allele was fixed to 1.00 and the relative activity
of all other alleles were scaled accordingly. The analysis
was then rerun with the EM (*1, *2, *35) and IM (*9, *10,
*17, *29, *41/*41XN) alleles included individually to
enable independent estimation of the N-DM-tam toD6 phenotype
UM (n = 5) EM (n = 119) IM (n = 214) PM (n = 17) P value*
49 52 52 46
43–61 30–95 24–88 38–78 0.17
69.8 71.6 71.1 70.0
48.6–78.7 44.2–149.1 32.1–135.4 47.6–140.7 0.93
80% 89.0% 78.8% 94.1%
20% 6.8% 19.8% 5.9%
0% 4.2% 1.4% 0% 0.006
10.1 11.1 9.9 13.1
6.2–16.5 3.8–116.3 3.4–72.1 3.7–39.8 0.64
0% 7.6% 1.9% 5.9% 0.03
20% 5.9% 2.4% 5.9% 0.16
0% 11.8% 8.0% 5.9% 0.53
20% 0.8% 0.5% 0% 1.00
CYP2D6 diplotype and allele activityendoxifen metabolic activity of each allele. Allele activity
was compared within the EM and IM allele types using
Kruskal–Wallis tests to determine whether any allele
was distinct from the group. Within each allele type the
mean activity of each individual allele was compared
with that of the most common allele within that group,
*1 for EM alleles and *41/*41XN for IM alleles.Figure 1
A) Baseline endoxifen concentration by CYP2D6 phenotype. Decreas-
ing CYP2D6 activity phenotype was associated with decreased
steady-state concentration of endoxifen (Kruskal–Wallis P< 0.0001).
CYP2D6 phenotype explained more than 10% of the variability in
endoxifen concentration. B) Baseline end : N-DM-tam ratio by CYP2D6
phenotype. Decreasing CYP2D6 activity phenotype was associated
with decreased steady-state ratio of endoxifen to N-desmethyl-tamox-
ifen (Kruskal–Wallis P < 0.0001). CYP2D6 phenotype explained more
than 18% of the variability in end : N-DM-tam ratioResults
After exclusion of six patients with inconclusive genotyp-
ing, 355 patients with EM (n=119), IM (n=214), PM
(n=17), or UM (n=5) predicted CYP2D6 phenotype were
eligible for inclusion in these analyses (Supplementary
Figure S1). Demographic data including age, weight, race,
time on tamoxifen prior to study consent and concomitant
CYP2D6 weak inhibitor use for the entire cohort and by
CYP2D6 phenotype can be found in Table 2. As expected,
race was unevenly distributed across CYP2D6 phenotypes
(P=0.006), as was the use of weak CYP2D6 inhibitors
(P=0.01). All other demographic factors were similar
(P >0.05). At baseline, with all patients receiving 20mg
tamoxifen, CYP2D6 phenotype was a significant
predictor of steady-state endoxifen concentration
(P< 0.0001, r2 = 0.11, Figure 1A) and end : N-DM-tam ratio
(P< 0.0001, r2=0.19, Figure 1B). Because predicted CYP2D6
phenotype explained 80% more variance in the metabolic
ratio, compared with endoxifen alone, the end : N-DM-tam
ratio was the focus of subsequent analyses.
Baseline differences between IM diplotypes
The 214 IM patients were further subdivided into four
distinct diplotypes (EM/IM: n=69, EM/PM: n= 89, IM/IM:
n=19, IM/PM: n=37). The CYP2D6 activity, estimated by
the end : N-DM-tam ratio when all patients were treated
with 20mg, varied significantly between these diplo-
types (P<0.0001). As expected, the ratio decreased with
decreasing activity of the component alleles, from the
highest activity EM/IM patients (median end : N-DM-tam
ratio = 0.061) to the lowest activity IM/PM patients
(end : N-DM-tam ratio = 0.024). When considering the
end : N-DM-tam ratio in the IM phenotype group only,
the diplotypes explained approximately 7.6% of the
variance. Similarly, the diplotypes were significantly asso-
ciated with baseline endoxifen concentration, though
the amount of variance explained was somewhat lower
(r2 = 0.047, P=0.0027).
Baseline differences between IM diplotype
extremes and EM or PM phenotypes
Across CYP2D6 diplotypes, the end : N-DM-tam ratio de-
creased with decreasing diplotype activity, as expected
(P< 0.0001, Figure 2). Compared with EM phenotype (EM/
EM) patients, the IM phenotype patients with the highest
activity diplotype (EM/IM) had significantly lower medianbaseline end : N-DM-tam ratios (0.061 vs. 0.082, P=0.0004,
Table 3) and endoxifen concentration (7.9 ng ml–1 vs.
8.9ng ml–1, P=0.033, Supplementary Table S1, Figure S2).
Similarly, when compared with PM (PM/PM) patients at
baseline, the IM diplotype group with the lowest activity
(IM/PM) had a greater end : N-DM-tam ratio (0.024 vs.
0.017, P=0.029) and a trend toward greater endoxifen con-
centration (4.0ng ml–1 vs. 2.4ng ml–1, P=0.068).
Differences between IM diplotypes and EM
phenotype at 4months
As previously reported, the endoxifen concentration for
the IM phenotype group on 40mg was similar to that of
the EM group on 20mg at the 4month time point [22],
but the PM group on 40mg did not achieve normalizedBr J Clin Pharmacol / 80:5 / 1125
Figure 2
Baseline end : N-DM-tam ratio by CYP2D6 diplotype. Decreasing
CYP2D6 diplotype was associated with decreased steady-state ratio of
endoxifen to N-desmethyl-tamoxifen (Kruskal–Wallis P < 0.0001).
Within the IM phenotype, the patients with the highest (EM/IM) and
lowest (IM/PM) activity diplophenoytpes were distinct from patients
with EM (EM/EM) or PM (PM/PM) activity, respectively
Table 4
Activity for each allele type relative to an EM allele fixed at 1.00
Allele
type n Median
Standard
deviation
Scaled
activity*
UM 9 0.056 0.053 0.85
EM 390 0.066 0.053 1.00
IM 149 0.044 0.034 0.67
PM 162 0.034 0.039 0.52
*Scaled to fix EM activity = 1.00 Note: Numbers of alleles do not match up with
previous tables due to the inclusion of UM allele carriers in this analysis but not
others.
D. L. Hertz et al.concentration. The 4month endoxifen concentration for
the EM phenotype (EM/EM) patients on 20mg was com-
pared with that of the IM diplotypes on 40mg. Only the
EM/PM and IM/IM diplotypes had similar endoxifen
concentrations after dose increase (P> 0.05), the EM/IM
patients had significantly greater endoxifen concentra-
tions (13.1 ng ml–1 vs. 8.2 ng ml–1, P<0.0001), and the
IM/PM patients remained significantly lower (5.8 ng ml–1
vs. 8.2 ng ml–1, P=0.0009) (Supplementary Table S2).
Modelling relative activity of allele types and
alleles
Using each patient’s two CYP2D6 alleles and their base-
line end : N-DM-tam metabolic ratio the relative activity
of each allele type (UM, EM, IM, PM) was estimated. Fixing
the activity of an EM allele to 1.00, the relative activity of a
UM, IM, and PM allele was estimated to be 0.85, 0.67 and
0.52, respectively (Table 4). The activity score modellingTable 3
Comparison of baseline endoxifen : N-desmethyl-tamoxifen ratio by CYP2D6 d
Phenotype Diplotype n (%)
Baseline end : N-DM-tam ratio
Median Standard deviation P value* vs
EM EM/EM 115 (33%) 0.082 0.058 NA
IM EM/IM 69 (20%) 0.061 0.030 0.0004
EM/PM 89 (26%) 0.045 0.043 <0.0001
IM/IM 19 (5%) 0.031 0.019 <0.0001
IM/PM 37 (11%) 0.024 0.033 <0.0001
PM PM/PM 17 (5%) 0.017 0.020 <0.0001
*value is based on the non-parametricWilcoxon rank-sum test †95% confidence interval for th
the difference in means (comparator diplotype – PM/PM)
1126 / 80:5 / Br J Clin Pharmacolanalysis was performed a second time with each EM
(*1, *2, *35) and IM (*9, *10, *17, *29, *41/*41XN) allele
included as an independent parameter. Individual al-
leles in the EM group had distinct metabolic activity
(P<0.0001). Fixing the wild-type (*1) allele activity to
1.00, the *2 allele had an estimated scaled activity of
0.63, which was significantly different from the *1 allele
(P=<0.0001, 95% CI 0.021, 0.041) while the *35 allele
had activity of 1.03, which was similar to *1 (Figure 3).
The individual IM alleles also had distinct metabolic ac-
tivity (P=0.014). Comparing each allele to the activity of
the most common *41/*41XN allele (activity = 0.53) only
*17 had a significantly different activity estimate (activ-
ity=0.39, 95% CI 0.005, 0.030, P=0.021). The scaled activity
of the other alleles ranged from 0.58–0.85 (Table 5). The
scaled activity of the UM and PM alleles changed marginally
to 0.71 and 0.43.Discussion
The original intent of this prospective genotype-guided
tamoxifen escalation study was to determine whether in-
creasing IM or PM patients to 40mg achieved endoxifen
concentrations similar to EM patients maintained on
20mg. As a composite phenotype group the IM patients
achieved similar endoxifen concentrations, but the PMiplotype
. EM/EM 95% CI† vs. EM/EM P value* vs. PM/PM 95% CI‡ vs. PM/PM
NA <0.0001 (0.058, 0.087)
(0.018, 0.044) <0.0001 (0.029, 0.054)
(0.024, 0.052) <0.0001 (0.021, 0.048)
(0.044, 0.72) 0.0032 (0.001, 0.028)
(0.041, 0.072) 0.029 (0.001, 0.030)
(0.058, 0.087) NA NA
e difference inmeans (EM/EM – comparator diplotype) ‡95% confidence interval for
Figure 3
Baseline end : N-DM-tam ratio by CYP2D6 allele. The EM and IM alleles
were analyzed separately to estimate their individual activity. The EM
alleles (*1, *2, *35) generally had greater activity. However, the *2 allele
had activity more similar to an IM or PM allele. The IM alleles represent a
continuum of activity that spans from activity similar to an EM allele (*9)
to activity similar to a PM allele (*17). The UM alleles were combined
due to small numbers and the PM alleles were combined because they
create non-functional protein or no protein at all, and thus have no
activity.
Table 5
Activity for each EM and IM allele relative to a wild-type *1 allele fixed at
1.00
Allele
type Allele n Median
Standard
deviation
Scaled
activity*
UM Composite 9 0.056 0.053 0.71
EM *1 (wild-type) 250 0.079 0.058 1.00
*2 109 0.050 0.036 0.63
*35 31 0.081 0.046 1.03
IM *9 20 0.067 0.029 0.85
*10 11 0.051 0.044 0.65
*17 21 0.031 0.022 0.39
*29 10 0.046 0.031 0.58
*41/*41XN 87 0.042 0.035 0.53
PM Composite 162 0.034 0.039 0.43
*Scaled to fix *1 activity = 1.00 Note: Numbers of alleles do not match up with
previous tables due to the inclusion of UM allele carriers in this analysis but not
others.
CYP2D6 diplotype and allele activitypatients remained below EM patients [22]. In this analysis
the IM diplotypes were analyzed separately. Doubling the
dose successfully achieved concentrations similar to those
of EM patients only for the EM/PM and IM/IM diplotypes.
The highest activity EM/IM patients may require a smaller
dose increase, as their endoxifen concentrations
exceeded those of the EM group. In some phenotype clas-
sification systems the EM/IM and EM/PM diplotypes are
collapsed with the EM, not the IM, phenotype. Thesepatients had endoxifen concentrations lower than the
EM/EM patients, suggesting that they may be underdosed
if they were considered EM patients and did not receive a
dose adjustment. Alternatively, this would prevent poten-
tial over-treatment in the EM/IM patients. Increasing the
lowest activity IM/PM patients to the maximum FDA-
approved 40mg dose is insufficient to achieve endoxifen
concentrations similar to that of EM patients. Though
genotype-guided tamoxifen dose escalation is not clini-
cally warranted at this time, our results indicate that
CYP2D6 genotype-guided treatment algorithms should
avoid collapsing the distinct IM diplotypes into a compos-
ite IM phenotype group.
Steady-state concentrations of tamoxifen metabolites
were used to evaluate CYP2D6 activity scoring systems
that categorize patients into four phenotypes (UM, EM,
IM, PM). The metabolic ratio of end : N-DM-tam was used
as it was nearly twice as reflective of CYP2D6 activity as
endoxifen alone, and may be more predictive of tamoxi-
fen treatment efficacy [14]. These results further suggest
that the IM phenotype is comprised of four diplotypes
(EM/IM, EM/PM, IM/IM, IM/PM) that have metabolic activity
distinct from each other and from the other CYP2D6
phenotype groups (EM or PM). Several CYP2D6 activity
scoring systems that return sometimes discordant
phenotypes have been proposed [23]. The Clinical Phar-
macogenetics Implementation Consortium (CPIC), which
publishes genetics-guided treatment recommendations
[24], has endorsed a system that assigns each allele an ac-
tivity score of 0 (PM), 0.5 (IM) or 1 (EM), which is multiplied
in the event of a gene duplication [5]. In this system EM/
PM (1 + 0=1.0) and IM/IM (0.5 + 0.5 =1.0) patients would
have equivalent activity, but EM/PM patients had on aver-
age 45% greater activity in this analysis (end : N-DM-tam
0.045 vs. 0.031, P=0.018). Using a scaled regression model
the activity for an IM allele (0.67) was similar to that (0.5)
used in existing systems. Interestingly, the empirical activ-
ity estimate of a PM allele (0.52) was much greater than
previously assumed. PM alleles have no CYP2D6 enzyme
activity as they are gene deletions or non-functional trun-
cated proteins. The activity estimated in this study is likely
attributable to alternative pathways for endoxifen forma-
tion including CYP3A4/5 and CYP2C9/19 [25].
The activity of each EM and IM allele was then esti-
mated and scaled to the activity of the wild-type *1 allele.
The relatively common *2 genotype (allele frequency in
this cohort =15.4%) is typically characterized as an EM al-
lele (activity = 1.0) but had an activity of only 0.63, which
is much closer in activity to an IM (0.67) allele. The in vitro
conversion of N-DM-tam to endoxifen for CYP2D6*2 has
been estimated as only 21% of the wild-type (*1) enzyme
[26] and a dextromethorphan pharmacokinetic study
reported that CYP2D6*2 had approximately 40% of the
activity of the wild-type [27]. Recently, the *2 SNP was
reported to alter exonic splicing and reduce gene expres-
sion [28]. Our results for tamoxifen bioconversion areBr J Clin Pharmacol / 80:5 / 1127
D. L. Hertz et al.consistent with prior results for dextromethorphan me-
tabolism, further supporting the need for reclassification
of *2 as an intermediate function allele. Unlike *2, the *35
EM allele had activity very similar to *1 (activity = 1.03)
and should continue to be considered a fully functional
allele. There was a wide range of activity within the IM al-
leles, with estimates as low as 0.39 (*17) and as high as
0.85 (*9). There is statistical evidence that these alleles
have distinct activity but the small number of some al-
leles makes it difficult to confirm which actually differ.
Similar to the previously discussed results for *2, ideally
the activity for each allele would be estimated in vitro
and confirmed in healthy controls in a pharmacokinetic
study using targeted pharmacogenetic enrolment.
There are several important limitations of this analy-
sis. Tamoxifen is metabolized by several enzymes and
the conversion to endoxifen has an alternate pathway.
The estimates in this analysis, such as the ‘activity’ seen
in non-functional PM alleles, reflect not just CYP2D6 ac-
tivity but also this alternative pathway. Unfortunately,
due to the small number of patients with UM phenotype
or UM alleles, it was not possible to assess whether the
activity of these diplotypes (UM: UM/UM and UM/EM,
EM: UM/IM and UM/PM) are distinct, should continue to
be collapsed into UM and EM phenotypes, or should be
collapsed into a single EM phenotype. Another limitation
of this analysis is the allele coverage of the AmpliChip
CYP450 Test™. This test only reports that a copy number
variant was detected, not the actual number of copies of
the gene, and is unable to detect certain rare variants
[29]. Additionally, some newly discovered functionally
consequential variants [30] and the 2988G>A variant
that defines the *41 haplotype [28] are missing from this
panel. This causes some *41 alleles to be erroneously
called *2, which would artificially depress the estimate
of *2 activity in this analysis. One final limitation is that
the genotype explained a relatively small proportion of
the variability in end : N-DM-tam ratio (18.6%), compared
with that in prior analyses (53–69%) [14, 25]. Log-
transformation marginally increased the variability ex-
plained (24%) but to improve interpretation of results
this was not done for the reported analyses. Several
other factors including inhibitor co-administration, pa-
tient size, and perhaps even the season of sample collec-
tion, may influence systemic concentrations of tamoxifen
metabolites [31]. Patients taking strong or moderate
CYP2D6 inhibitors were excluded from this study but
these other factors were not accounted for in drug dos-
ing or in this analysis. Additional clinical and genetic
factors, including variants in other enzymes and trans-
porters [32], will be included in follow-up analyses
attempting to validate and extend a previously pub-
lished endoxifen prediction algorithm [31].
In conclusion, pharmacogenetic–pharmacokinetic
analysis of steady-state tamoxifen metabolite concentra-
tions confirms that predicted CYP2D6 phenotypes are1128 / 80:5 / Br J Clin Pharmacolcomprised of metabolically distinct diplotypes that
should not be collapsed in genotype-guided dosing
algorithms. Furthermore, currently used activity scoring
systems are not optimally calibrated, specifically in
regards to the *2 genotype which does not have full
activity. Due to the inconsistent findings regarding the
relationship of CYP2D6 genotype and tamoxifen efficacy,
it is unclear whether these results will be useful for
personalizing dosing of tamoxifen. However, these
results highlight the need for further research to calibrate
optimally CYP2D6 phenotype systems to guide persona-
lized dosing of other CYP2D6-dependent drugs such as
codeine [5] and tricyclic anti-depressants [6].Competing Interests
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